IMI launches Call for proposals on antimicrobial resistance
IMI officially launched its 6th Call for proposalson ‘Combating Antibiotic Resistance – NewDrugs4BadBugs (ND4BB)’ on 24 May 2012. The Call comprises two topics:
Topic 1, on innovative trial design and clinical drug development, is broken down into two subtopics (1A and 1B).
Topic 2 is on ‘learning from success and failure and getting drugs into bad bugs’.
The deadline for submitting Expressions of Interest in response to this Call is 9 July 2012. Applicants are strongly advised to read the Call text and related material thoroughly. Any questions relating to the Call text or the application procedure should be sent to Infodesk@imi.europa.eu
Learn more about the 6th Call at the Stakeholder Forum
IMI’s Stakeholder Forumon Wednesday 30 May in Brussels will feature an info session / workshop on the antimicrobial resistance topic. During the workshop, the EFPIA topic coordinators will present the project and there will be plenty of time for questions and answers. The Stakeholder Forum also represents an excellent opportunity to network with fellow applicants, and the registration tool allows participants to set up meetings with one another in advance.
Sign up to the 6th Call webinars
IMI will hold webinarson the 6th Call for proposals on Thursday 24 May at 15:00, and Friday 25 May at 14:00. For those who cannot attend the Stakeholder Forum, the webinars represent a chance to learn more about the topics and interact directly with the EFPIA topic coordinators.
Future Calls for proposals on antimicrobial resistance
Topic 1 of the 6th Call for proposals (on innovative trial design & clinical drug development) includes a third subtopic (1C), which will be launched later this year under a new Call for proposals. Additional Calls for proposals addressing further research topics in relation to antimicrobial resistance will follow throughout 2012 and 2013. To stay up to date with the launch of these and other Calls for proposals, visit the IMI websiteregularly!
An outline of IMI’s indicative topic on ‘building a sustainable framework for rapid assessment of vaccination benefit/risk in Europe’ is now available on IMI’s Future Topicsweb page. Vaccines are one of the most effective public health measures, with millions of people vaccinated every year. However public distrust has been growing in recent years, fuelled by fear of safety issues. The aim of the project would be to develop a sustainable infrastructure for facilitating post-approval, rapid and integrated assessment of the benefit/risk of vaccines. The topic is under consideration for inclusion in IMI’s 7th Call for proposals.